close

Agreements

Date: 2017-06-15

Type of information: Nomination

Compound: chief operating officer

Company: VBL Therapeutics (Israel)

Therapeutic area: Cancer - Oncology

Type agreement: nomination

Action mechanism:

Disease:

Details:

  • • On June 15, 2017, VBL Therapeutics announced the appointment of Corinne Epperly, MD, MPH, as U.S. Chief Operating Officer. Dr. Epperly is an oncology expert with industry background in drug development, strategy, commercialization and operations. She will have key responsibilities in forming VBL's marketing strategy and commercialization plan for its Phase 3 candidate VB-111 and will work with VBL's leadership team to advance corporate strategy and U.S. activities. Dr. Epperly will report to Dr. Dror Harats, Chief Executive Officer of VBL.
  • Dr. Epperly joins VBL after seven years at BMS, where she delivered results across diverse roles spanning marketing, M&A, strategic operations and medical strategy. Most recently she was involved in leading the preparation for the commercial launches of OPDIVO® (nivolumab) in both hepatocellular carcinoma and in glioblastoma. While at BMS she led U.S. immuno-oncology safety management, advancing the safety strategy with oncology stakeholders. Dr. Epperly also served as the Global Mergers & Acquisitions Lead in the Strategic Transactions Group at BMS. Prior to joining BMS, she was a member of the Global Healthcare Investment Research team at Goldman Sachs, based in London, where she helped relaunch the European Pharmaceutical and Biotech Team. Dr. Epperly holds a dual graduate degree, an M.D. and an MPH from the University of North Carolina at Chapel Hill. She completed her medical training at the University of North Carolina Hospitals with the Department of Pediatrics. She also earned a Distinguished B.A. from the University of Virginia where she studied biochemistry and biology. Prior to medical school she conducted biomedical research in Experimental Immunology on checkpoint inhibition and tumor suppressor genes in the National Cancer Institute, National Institutes of Health.

Financial terms:

Latest news:

Is general: Yes